News & Updates

Patients with ST-segment elevation myocardial infarction (STEMI)-related cardiogenic shock may benefit from a significantly higher survival rate at 6 months through the routine use of a microaxial flow pump in combination with standard care as compared with standard care alone, as shown in a study presented at the recent ACC.24.

Children and adolescents with Tourette syndrome (TS) may benefit from ecopipam, a first-in-class selective dopamine-1 (D1) receptor antagonist, as it reduced the number of tics and level of daily interference in a post hoc analysis of the phase IIb D1AMOND trial.